The utility of anthracycline antineoplastic agents in the clinic is compromised by the risk of
cardiotoxicity. It has been calculated that approximately 10% of patients treated with …

Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers.
Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite …

Background: Cancer therapy–induced cardiomyopathy (CCM) is associated with cumulative
drug exposures and preexisting cardiovascular disorders. These parameters incompletely …

The goal of this study is to give a brief background on the literature supporting the
PharmGKB pathway about doxorubicin action, and provides a summary of this active area of …

1928 Circulation October 22, 2013 mental health, functional status, activity limitations,
cancerrelated pain, and cancer-related anxiety) declined moderately to severely in 44%. 5 …

Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery
disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a …

Anthracyclines are used in over 50% of childhood cancer treatment protocols, but their
clinical usefulness is limited by anthracycline-induced cardiotoxicity (ACT) manifesting as …

Survival for childhood cancer has increased dramatically over the last 40 years with 5-year
survival rates now approaching 80%. For many diagnostic groups, rapid increases in …

Purpose Anthracycline-induced cardiotoxicity (ACT) is a serious adverse drug reaction
limiting anthracycline use and causing substantial morbidity and mortality. Our aim was to …

Aims Anthracycline‐induced cardiotoxicity (ACT) occurs in 57% of treated patients and
remains an important limitation of anthracycline‐based chemotherapy. In various genetic …